Ethical issues in rheumatology clinical trials
Authors:
- 10 June 2008
- journal article
- review article
- Published by Springer Nature in Nature Clinical Practice Rheumatology
- Vol. 4 (7) , 356-363
Abstract
Clinical trials in rheumatology, similar to other areas of research, are associated with a plethora of ethical issues. Relevant issues, depending on the type of trial (for example, early phase trials, prevention trials and postmarketing studies), are outlined in this article, along with issues related to the selection of control arms for clinical trials, the selection of relevant outcome measures and some of the challenges in obtaining informed consent. Clinical trials in rheumatology are necessarily associated with an array of ethical issues that vary according to the type of trial under consideration. Difficult questions arise related to the appropriateness of enrolling normal volunteers or patients with disease in early phase toxicity studies of new agents. Prevention studies raise important questions regarding the exposure of a population of patients to an intervention with known adverse effects, even though prevention is not ensured. Postmarketing studies, although critically important in determining the true and long-term effects of therapies in a real-world setting, are sometimes designed solely for marketing purposes that do not contribute to meeting such goals. Regardless of the type of trial, selecting the appropriate control arm, the outcome measure, and 'rescue' or withdrawal provisions requires attention to pragmatic as well as ethical concerns. In addition, randomization is only ethically appropriate when, in addition to other conditions, clinical equipoise pertains to the treatment arms. Additional formative research is needed to improve the design of clinical trials and the informed consent processes for them. Finally, training in clinical research methods, which encompasses research ethics, is needed for rheumatologist investigators to ensure that participants are protected and that the results obtained from studies will be sound and ultimately applicable to clinical care.Keywords
This publication has 35 references indexed in Scilit:
- Congress Responds to the IOM Drug Safety Report—In FullJAMA, 2007
- Serious infection following anti–tumor necrosis factor α therapy in patients with rheumatoid arthritis: Lessons from interpreting data from observational studiesArthritis & Rheumatism, 2007
- Anti–tumor necrosis factor α therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritisArthritis & Rheumatism, 2007
- Preventive MisconceptionAmerican Journal of Preventive Medicine, 2007
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: Comparison of patients according to their eligibility for major randomized clinical trialsArthritis & Rheumatism, 2006
- “Special Scrutiny”: A Targeted Form of Research Protocol ReviewAnnals of Internal Medicine, 2004
- Uneasy Alliance — Clinical Investigators and the Pharmaceutical IndustryNew England Journal of Medicine, 2000
- Gastrointestinal Tract Complications of Nonsteroidal Anti-inflammatory Drug Treatment in Rheumatoid ArthritisArchives of internal medicine (1960), 1996
- The relative toxicity of disease‐modifying antirheumatic drugsArthritis & Rheumatism, 1993